Condition: Acute Myeloid Leukemia (AML) · Sponsor: Servier Affaires Médicales
The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \[IDH1m\]) and cannot receive treatment with intensive chemotherapy (IC).
This description comes directly from the study's public registry record.
Servier Affaires Médicales · +33 1 55 72 60 00 · scientificinformation@servier.com
Always discuss trial participation with your own doctor first.
| AKH - Medizinische Universität Wien | Vienna, Austria | Completed |
| Klinikum Wels-Grieskirchen GmbH | Wels, Austria | Completed |
| Institut Paoli Calmettes | Marseille, Bouches-du-Rhône, France | Recruiting |
| CHU CAEN - Hôpital de la Côte de Nacre | Caen, Calvados, France | Recruiting |
| CHU de Toulouse pt | Toulouse, Haute Garonne, France | Recruiting |
| CHU Rennes - Hopital Pontchaillou | Rennes, Ille Et Vilaine, France | Not Yet Recruiting |
| CHU Angers - Hôpital Hôtel Dieu | Angers, Liore, France | Not Yet Recruiting |
| IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST | Meldola, Forli-Cesena, Italy | Recruiting |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) | Brescia, Italy | Recruiting |
| IRCCS Ospedale Policlinico San Martino | Genova, Italy | Recruiting |
| Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia | Perugia, Italy | Recruiting |
| Meander Medisch Centrum | Amersfoort, Netherlands | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05907057